Low levels of asymmetric dimethylarginine in children with diabetes mellitus type I compared with healthy children

Journal of Pediatrics

Volumn 158, Issue 4, 2011, Pages

  Huemer, Martina ^a,h   Simma, Burkhard ^b   Mayr, Dieter ^a   Mühl, Adolf ^c   Rami, Birgit ^d   Schober, Edith ^d   Ulmer, Hanno ^e   Zanier, Ulrike ^f   Bodamer, Olaf A ^g  

^a Landeskrankenhaus Bregenz ^*  (Austria)

^b Landeskrankenhaus Feldkirch   (Austria)

^c CENTOGENE AG   (Germany)

^d ST ANNA CHILDREN S HOSPITAL   (Austria)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^f Krankenhaus Dornbirn   (Austria)

^g Children's Hospital Salzburg   (Austria)

^h UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE;

ADOLESCENT; AMINO ACID BLOOD LEVEL; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD ANALYSIS; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK ASSESSMENT; SCHOOL CHILD; VASCULAR DISEASE;

EID: 79952575437     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2010.09.058     Document Type: Article

References (26)

1. Böger RH, Maas R, Schulze F, Schwedhelm E. Elevated levels of asymmetric dimethylarginine (ADMA) as a marker of cardiovascular disease and mortality. Clin Chem Lab Med 2005;43:1124-9. (Pubitemid 41581972)
2. Finkelstein JD. Pathways and regulation of homocysteine metabolism in mammals. Semin Thromb Hemost 2000;26:219-25.
3. Siroen MP, van Leeuwen PA, Nijveldt RJ, Teerlink T, Wouters PJ, Van den Berghe G. Modulation of asymmetric dimethylarginine in critically ill patients receiving intensive insulin treatment: a possible explanation of reduced morbidity and mortality? Crit Care Med 2005;33:504-10.
4. Böger RH. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor. J Nutr 2004;134:S2842-7.
5. Schulze F, Lenzen H, Hanefeld C, Bartling A, Osterziel KJ, Goudeva L, et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination Investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J 2006;152:493.e1-8.
6. Kari JA, Donald AE, Vallance DT, Bruckdorfer KR, Leone A, Mullen MJ, et al. Physiology and biochemistry of endothelial function in children with chronic renal failure. Kidney Int 1997;52:468-72. (Pubitemid 27359590)
7. Goonasekera CD, Rees DD, Woolard P, Frend A, Shah V, Dillon MJ. Nitric oxide synthase inhibitors and hypertension in children and adolescents. J Hypertens 1997;15:901-9. (Pubitemid 27344855)
8. Goonasekera CD, Shah V, Rees DD, Dillon MJ. Vascular endothelial cell activation associated with increased plasma asymmetric dimethyl arginine in children and young adults with hypertension: a basis for atheroma? Blood Press 2000;9:16-21.
9. GorenfloM,Zheng C,Werle E, FiehnW, UlmerHE. Plasma levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension. J Cardiovasc Pharmacol 2001;37:489-92.
10. Altinova AE, Arslan M, Sepici-Dincel A, Akturk M, Altan N, Toruner FB. Uncomplicated type 1 diabetes is associated with increased asymmetric dimethylarginine concentrations. J Clin Endocrinol Metab 2007;92:1881-5. (Pubitemid 46997204)
11. Tarnow L, Hovind P, Teerlink T, Stehouwer CDA, Parving HH. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care 2004;27:765-9. (Pubitemid 38280547)
12. Heilman K, Zilmer M, Zilmer K, Kool P, Tillman V. Elevated plasma adiponectin and decreased plasma homocysteine and asymmetric dimethylarginine in children with type 1 diabetes. Scand J Clin Lab Invest 2009;69:85-91.
13. Pitocco D, Zaccardi F, Di Stasio E, Romitelli F, Martini F, Scaglione GL, et al. Role of asymmetric-dimethyl-L-arginine (ADMA) and nitrite/nitrate (NOx) in the pathogenesis of oxidative stress in female subjects with uncomplicated type 1 diabetes mellitus. Diab Res Clin Pract 2009;86:173-6.
14. Martens-Lobenhoffer J, Bode-Boger SM. Fast and efficient determination of arginine, symmetric dimethylarginine, and asymmetric dimethylarginine in biological fluids by hydrophilic-interaction liquid chromatography-electrospray tandem mass spectrometry. Clin Chem 2006;52:488-93.
15. Leino A. Fully automated measurement of total homocysteine in plasma and serum on the Abbott IMx Analyzer. Clin Chem 1999;45:569a-70a.
16. Steijns LS, Braams-Wiatrowska JK, Luiting HJ, van der Weide J. Evaluation of nonisotopic binding assays for measuring vitamin B12 and folate in serum. Clin Chim Acta 1996;30(248):135-41.
17. Cighetti G, Fermo I, Aman CS, Ferraroni M, Secchi A, Fiorina P, et al. Dimethylarginines in complicated type 1 diabetes: roles of insulin, glucose and oxidative stress. Free Radic Biol Med 2009;47:307-11.
18. Abhary S, Kasmeridis N, Burdon KP, Kuot A, Whiting ME, Yew WP, et al. Diabetic retinopathy is associated with elevated serum asymmetric and symmetric dimethylarginines. Diabetes Care 2009;32:2084-6.
19. Böger RH, Zoccali C. ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease. Atheroscler Suppl 2003;4:23-8. (Pubitemid 38234491)
20. Marcovecchio ML, Widmer B, Dunger DB, Dalton RN. Effect of acute variations of insulin and glucose on plasma concentrations of asymmetric dimethylarginine in young people with type 1 diabetes. Clin Sci 2008; 115:361-9.
21. Raes A, Donckerwolcke R, Craen M, Che Hussein M, Vande Walle J. Renal hemodynamic changes and renal function reserve in children with type 1 diabetes mellitus. Pediatr Nephrol 2007;22:1903-9. (Pubitemid 47506231)
22. Pitocco D, Di Stasio E, Romitelli F, Zaccardi F, Tavazzi B, Manto A, et al. Hypouricemia linked to an overproduction of nitric oxides is an early marker of oxidative stress in female subjects with type 1 diabetes. Diabetes Metab Res Rev 2008;24:318-23. (Pubitemid 351802797)
23. Dominguez C, Ruiz E, Gussinye M, Carrascosa A. Oxidative stress at onset and in early stages of type 1 diabetes in children and adolescents. Diabetes Care 1998;21:1736-42. (Pubitemid 28449817)
24. Sydow K, Münzel T. ADMA and oxidative stress. Atheroscler Suppl 2003;4:41-51. (Pubitemid 38234494)
25. Lücke T, Kanzelmeyer N, Kemper MJ, Tsikas D, Das AN. Developmental changes in the L-arginine/nitric oxide pathway from infancy to adulthood: plasma asymmetric dimethylarginine levels decrease with age. Clin Chem Lab Med 2007;45:1525-30. (Pubitemid 350036557)
26. Kostolanska J, Jakus V, Barak L. HgA1c and serum levels of advanced glycation and oxidation protein products in poorly and well-controlled children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2009;22:433-42.